• Opus Genetics Inc IRD.OQ reported a quarterly adjusted loss of 29 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of 25 cents. The mean expectation of four analysts for the quarter was for a loss of 24 cents per share. Wall Street expected results to range from -30 cents to -10 cents per share.

• Revenue fell 67.6% to $3.87 million from a year ago; analysts expected $2.29 million.

• Opus Genetics Inc's reported EPS for the quarter was a loss of 29 cents​.

• The company reported a quarterly loss of $7.53 million.

• Opus Genetics Inc shares had fallen by 10.7% this quarter and lost 61.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 5% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Opus Genetics Inc is $10.00

This summary was machine generated from LSEG data November 12 at 03:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)